Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results

A. van der Laan, A. Hirsch, R. Nijveldt, P. A. van der Vleuten, W. J. van der Giessen, P. A. Doevendans, J. Waltenberger, J. M. ten Berg, W. R. M. Aengevaeren, J. J. Zwaginga, B. J. Biemond, A. C. van Rossum, J. G. P. Tijssen, F. Zijlstra, J. J. Piek

Research output: Contribution to journalArticleAcademicpeer-review

39 Citations (Scopus)


During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE Study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary, infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary, BMMC therapy on post-infact left ventricular. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. (Neth Hcart J 2008;16:436-9.)
Original languageEnglish
Pages (from-to)436-439
JournalNetherlands heart journal
Issue number12
Publication statusPublished - 2008

Cite this